N-tert-butyl-N,4-dimethylpentan-1-amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-tert-butyl-N,4-dimethylpentan-1-amine
• 化学式: C₁₁H₂₅N
• 分子量: 171.32
• InChiKey: PWEBQADPBANXLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Methods of using nucleotide analogues
  申请人：Intelligent BioSystems, Inc.

  公开号：US10273539B2

  公开（公告）日：2019-04-30

  The present invention provides methods, compositions, mixtures and kits utilizing deoxynucleoside triphosphates comprising a 3′-O position capped by a group comprising methylenedisulfide as a cleavable protecting group and a detectable label reversibly connected to the nucleobase of said deoxynucleoside. Such compounds provide new possibilities for future sequencing technologies, including but not limited to Sequencing by Synthesis.

  本发明提供了利用脱氧核苷三磷酸酯的方法、组合物、混合物和试剂盒，该脱氧核苷三磷酸酯包含一个 3′-O 位点，该位点被一个包含亚甲基二硫化物的基团封盖，该基团是一个可裂解的保护基团，以及一个与所述脱氧核苷的核碱基可逆连接的可检测标签。这种化合物为未来的测序技术提供了新的可能性，包括但不限于合成测序技术。
• METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS
  申请人：NOVARTIS AG

  公开号：US20140134262A1

  公开（公告）日：2014-05-15

  The present invention provides a compound of Formula I: for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride level; wherein R 1 , X 1 , R 7 , R 5 , C, L and p are defined herein. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of diseases and conditions associated with CETP activity, such as atherosclerosis and dyslipidemia, in a subject with high triglyceride levels.
• Fused-Ring Or Tricyclic Aryl Pyrimidine Compound Used As Kinase Inhibitor
  申请人：GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

  公开号：US20180072704A1

  公开（公告）日：2018-03-15

  Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.
• INHIBITION OF OLIG2 ACTIVITY
  申请人：Curtana Pharmaceuticals, Inc.

  公开号：US20200407329A1

  公开（公告）日：2020-12-31

  Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.